These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 23564821)
1. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254 [TBL] [Abstract][Full Text] [Related]
3. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836 [TBL] [Abstract][Full Text] [Related]
4. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806 [TBL] [Abstract][Full Text] [Related]
6. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084 [TBL] [Abstract][Full Text] [Related]
7. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting. Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423 [TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P; J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer. Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer. Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297 [TBL] [Abstract][Full Text] [Related]
12. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854 [TBL] [Abstract][Full Text] [Related]
13. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762 [TBL] [Abstract][Full Text] [Related]
15. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768 [TBL] [Abstract][Full Text] [Related]
16. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400 [TBL] [Abstract][Full Text] [Related]
17. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556 [TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-related cardiac events in the treatment of early breast cancer. Fried G; Regev T; Moskovitz M Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507 [TBL] [Abstract][Full Text] [Related]
19. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? Castrellon AB; Glück S Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]